CurrentCapital BluecrossPolicy AHS - G2045 - Thyroid Disease Testing

Thyroid Disease Testing

Clinical coverage policy describing when thyroid function and antibody tests are medically necessary, monitoring intervals, and tests considered not covered; applies to Capital Bluecross members.

Policy Summary

PayerCapital Bluecross

PolicyThyroid Disease Testing

Policy CodePolicy AHS - G2045 - Thyroid Disease Testing

Change TypeNo material change

Effective Date

Next Review Date

Key ActionStart evaluation with TSH as the preferred first-line test and document clinical indications when ordering additional thyroid tests.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 weeksmonitoring interval after dose change for primary hypothyroidism or hyperthyroidism

annualroutine monitoring frequency for stable treated thyroid disease

3 yrsthyroid antibody testing interval for hypo- or hyperthyroidism

>10distinct covered or not-covered test conditions listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

procedure codes listed

Coverage Criteria for Thyroid Disease Testing

Medical necessity criteria

Covered when the specific clinical scenarios or monitoring intervals below are met

Diagnostic testing for symptomatic individuals: TSH testing to confirm or rule out primary hypothyroidism; follow-up free T4 (fT4) when TSH is abnormal; TSH and fT4 testing in suspected secondary (central) hypothyroidism.

See Note 1 and Note 2 for symptom lists.

Diagnostic testing for hyperthyroidism: TSH testing to confirm or rule out overt hyperthyroidism; follow-up fT4 when TSH is abnormal; total T3 (TT3) or free T3 (fT3) testing to confirm hyperthyroidism or to evaluate T3 thyrotoxicosis.

Monitoring treated disease: Primary hypothyroidism: TSH and fT4 every 6 weeks after dose change and annually when stable. Secondary hypothyroidism: fT4 every 6 weeks after dose change and annually when stable. Hyperthyroidism: repeat TSH and fT4 every 6 weeks during treatment and annual monitoring after the first year.6 weeks; annual

Pregnancy/postpartum: For pregnant or postpartum individuals with symptoms of thyroid dysfunction: TSH and fT4 testing once every 4 weeks. In pregnant individuals diagnosed with hyperthyroidism, TT4, Tg‑Ab, TRAb, and TPOAb meet coverage criteria.every 4 weeks

Use trimester-specific lab ranges for fT4; TT4 acceptable if fT4 ranges unavailable or discordant.

One-time screening for high-risk asymptomatic individuals: One-time TSH screening for asymptomatic individuals at high risk (personal/family history of thyroid dysfunction; personal/family history of type 1 diabetes or other autoimmune disease; disease or neoplasm of thyroid or other endocrine glands; chronic or acute urticaria; pediatric short stature; or two or more pregnancy losses).one-time

Special populations and indications: TSH every 3 months with reflex fT4 and fT3 when abnormal for individuals undergoing immune reconstitution therapy (e.g., alemtuzumab for MS, HIV on HAART); testing for individuals after allogeneic BMT/HSCT; biannual TSH and fT4 monitoring for <18 years with hypothalamic‑pituitary disease and annual thereafter; annual TSH and fT4 for primary mitochondrial disease.3 months; biannual; annual

Thyroid cancer surveillance: Serum thyroglobulin and/or thyroglobulin antibody (Tg‑Ab) testing for detection of tumor recurrence, post‑surgical evaluation, surveillance and maintenance for differentiated thyroid carcinomas.

Tests not meeting routine coverage in most situations: Testing for TRH or TBG, reverse T3, T3 uptake, and TT4 for unspecified indications does NOT meet coverage criteria. Routine measurement of TT3 or fT3 to assess hypothyroidism or to guide levothyroxine dosing does NOT meet coverage criteria except where specifically indicated.

Guideline-aligned testing criteria

Covered when testing follows guideline-based indications and documentation:

Pregnancy-related testing: TSH is the first-line test in pregnancy; apply trimester- and method-specific reference ranges. Monitor TSH in pregnant individuals treated for hypothyroidism and adjust levothyroxine to a goal TSH between the lower reference limit and 2.5 mIU/L; measure TT3 or TRAb when clinically indicated (e.g., suspected hyperthyroidism or history of Graves' disease).TSH goal <= 2.5 mIU/L in pregnancy when adjusting therapy

Use method-specific and trimester-specific fT4 reference ranges; if fT4 assay not available, total T4 may be preferred when discordant with TSH.

Autoantibody testing: Consider TPOAb measurement when evaluating subclinical hypothyroidism or recurrent miscarriage. Consider TSH receptor antibody (TRAb) testing in pregnant patients with prior Graves' disease at 20–26 weeks or earlier if indicated.

Routine TPOAb screening in euthyroid women is not recommended.

Initial diagnostic approach in nonpregnant patients: Measure serum TSH as the preferred initial test for suspected hypo‑ or hyperthyroidism; reserve fT4, fT3, and total T3 testing for specific clinical contexts (confirmation of overt dysfunction, T3 thyrotoxicosis, or central hypothyroidism where fT4 is preferred). Avoid routine T3/fT3 testing per guidelines unless clinically justified.

Guideline-driven indications and monitoring

Covered when testing or monitoring aligns with specialty society recommendations and specified clinical indications

Initial evaluation of suspected primary thyroid dysfunction: TSH measurement is indicated as the initial test; if TSH is abnormal, obtain free T4 (fT4).

ASCP, Endocrine Society, AJGP support starting with TSH and confirming with fT4

When to measure autoantibodies: TPOAb should be considered in evaluation of subclinical hypothyroidism and recurrent miscarriage; TRAb/TSH‑R‑Ab measurement is recommended in pregnant patients with history of Graves' disease or when hyperthyroidism is suspected to guide fetal monitoring.

ATA/AACE and ETA guidance

Pregnancy-specific testing: Use trimester- and assay-specific reference ranges for TSH and fT4; measure TSH early in pregnancy in women with risk factors and monitor TSH every 4 weeks in at‑risk or treated pregnant women until mid‑gestation, then per guideline intervals; consider TRAb testing at ~20–24 weeks if history of Graves' disease.first trimester 0.1–2.5 mIU/L; second 0.2–3.0; third 0.3–3.0

Central hypothyroidism: diagnostic and screening criteria

Diagnosis of central hypothyroidism is supported when ALL of the following are met:

Diagnostic confirmation: Serum FT4 concentrations below the lower limit of the normal range AND inappropriately low or normal TSH concentrations on at least two separate determinations, after exclusion of listed conditions.2 separate determinations

Confirm after exclusion of conditions reported in policy Table 3.

Clinical contexts prompting consideration of CeH: Findings prompting evaluation include neonates/children with congenital hypothyroidism manifestations but low/normal neonatal TSH; patients with hypothalamic or pituitary lesions, head trauma, stroke, cranial irradiation, hemochromatosis/iron overload; familial history or features such as failure‑to‑thrive, developmental delay, GH deficiency, delayed/precocious puberty, macroorchidism (IGSF1 defect); or symptoms suggestive of hypothalamic‑pituitary disease (eg hyperprolactinemia, acromegaly features, diabetes insipidus, recurrent headaches, visual field defects).

ETA recommendations list multiple specific indications

Medication or treatment triggers for evaluation:

NICE: testing cascade and monitoring intervals

NICE testing and monitoring guidance (consider/measure and test frequency):

Initial testing in adults when secondary dysfunction is not suspected: Measure TSH alone; if TSH is above the reference range measure FT4 in the same sample; if TSH is below the reference range measure FT4 and FT3 in the same sample.

Recommendation 1.2.8

Initial testing when secondary dysfunction suspected or for children/young people: Measure both TSH and FT4; if TSH is below the reference range, measure FT3 in the same sample.

Recommendation 1.2.9

Monitoring frequency for adults on levothyroxine: Measure TSH every 3 months until stabilized (defined as two similar measurements within the reference range 3 months apart), then annually; consider FT4 with TSH if symptoms occur after starting levothyroxine.stabilized = 2 similar measures 3 months apart

NICE guidance

Tests such as thyrotropin‑releasing hormone (TRH) stimulation panels and thyroxine‑binding globulin (TBG) measurement are not covered for evaluation of the cause of hypo‑ or hyperthyroidism. The policy also states that routine use of reverse T3, T3 uptake, and total T4 (TT4) for unspecified indications does not meet coverage criteria and may be denied.

Measurement of total or free T3 (TT3 or fT3) for assessment of hypothyroidism or to guide levothyroxine dosing is specifically listed as not meeting coverage criteria, and the policy advises reserving T3 testing for clinical situations (for example, suspected thyrotoxicosis) where guideline-based indications exist.

The United States Preventive Services Task Force (USPSTF) concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for thyroid dysfunction in nonpregnant, asymptomatic adults; USPSTF also recommends against routine thyroid cancer screening in asymptomatic adults.

Multiple specialty societies advise against routine universal screening of asymptomatic, nonpregnant adults and caution about ordering multi‑test thyroid panels at annual wellness visits. The American Society for Clinical Pathology recommends starting with TSH for initial evaluation and avoiding multiple tests up front; ATA/AACE and the Endocrine Society similarly discourage indiscriminate multi‑test ordering when TSH‑first testing is appropriate.

NICE guidance indicates clinicians should not perform thyroid testing solely because a patient has type 2 diabetes or an unrelated acute illness. NICE recommends targeted testing based on clinical suspicion and follows a cascade approach (TSH first in most adults, with FT4/FT3 added depending on TSH result).

The references section of the policy provides supporting literature but does not itself establish explicit coverage exclusions beyond those stated elsewhere in the document.

Testing for thyroid dysfunction performed during a routine general exam in asymptomatic, nonpregnant individuals with no abnormal findings does not meet coverage criteria. Societal guidance (ASCP) similarly advises against routine TSH screening at annual well visits in asymptomatic adults unless risk factors or clinical signs are present.

Routine measurement of T3 or fT3 for monitoring patients with hypothyroidism on levothyroxine is not recommended and offers limited clinical utility. Studies cited in the policy and Endocrine Society guidance conclude that T3 testing does not generally inform levothyroxine dose adjustments and should be avoided for routine monitoring.

The policy discourages routine measurement of reverse T3 and routine asymptomatic screening. It reiterates that routine T3 measurement to guide levothyroxine dosing is unsupported by guidelines; instead, a stepwise approach beginning with TSH (with reflex FT4/FT3 where clinically indicated) is recommended to avoid unnecessary testing and costs.

The Society for Maternal‑Fetal Medicine (SMFM) recommends against universal screening of asymptomatic pregnant individuals for subclinical hypothyroidism. Other reproductive and obstetric bodies (ASRM, ACOG, ATA) endorse targeted TSH testing in pregnancy for women with risk factors or symptoms rather than routine population‑level screening.

While the references section lists the source literature underpinning the policy, it does not include additional 'not medically necessary' statements beyond those explicitly stated in the main policy text.

Applicable Procedure Codes

Applicable CPT/HCPCS Procedure CodesCPT

80438	Thyrotropin-releasing hormone (TRH) stimulation panel; 1 hour This panel must include the following: Thyroid stimulating hormone (TSH) (84443 x 3).
80439	Thyrotropin-releasing hormone (TRH) stimulation panel; 2 hour This panel must include the following: Thyroid stimulating hormone (TSH) (84443 x 4).
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA).
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified.
84432	Thyroglobulin.
84436	Thyroxine; total.
84439	Thyroxine; free.
84442	Thyroxine-binding globulin (TBG).
84443	Thyroid stimulating hormone (TSH).
84445	Thyroid stimulating immune globulins (TSI).

1–10 of 16

1/2

Provider Actions, Documentation, and Billing Guidance

Documentation Required

Preferred Initial Test and Stepwise Diagnostic Approach

Start with TSH as the preferred initial test for suspected thyroid dysfunction; reserve fT4, fT3, TT3, and antibody testing for situations where guidelines indicate (e.g., abnormal TSH, pregnancy, suspected central hypothyroidism, or hyperthyroidism workup). Avoid ordering multiple initial tests simultaneously unless clinically justified.

Preferred initial test: TSH as first-line screening
Do not substitute routine fT3/TT3 for initial assessment of hypothyroidism

Documentation Required

Stepwise Diagnostic Approach

Follow a stepwise diagnostic approach: measure TSH first; if abnormal, obtain a reflex or subsequent free T4 (fT4). If central (secondary) hypothyroidism is suspected, measure both TSH and fT4 together. For suspected hyperthyroidism with low TSH, consider fT4 and, when indicated, TT3 or fT3 to define T3 thyrotoxicosis or guide management.

Step 1: TSH alone for most non-pregnant adults unless secondary thyroid disease suspected
Step 2: If TSH abnormal, add fT4 (and fT3/TT3 if TSH suppressed and clinical picture suggests T3 thyrotoxicosis)

Background and Rationale

Thyroid hormones (principally T4 and T3) regulate growth, development, and metabolic homeostasis. Thyroid disease encompasses a spectrum from hypothyroidism to hyperthyroidism, thyroiditis, goiter, and neoplasia. Laboratory testing—primarily TSH as the first‑line diagnostic test with reflex or adjunct free T4 (fT4) and T3/fT3 when indicated—is central to diagnosis and monitoring; pregnancy requires application of trimester‑specific reference ranges for interpretation.

Definitions and Key Terms

TSH — Thyroid stimulating hormone definition and role

DefinitionThyroid stimulating hormone (TSH) — a pituitary-derived glycoprotein that regulates thyroid hormone production and is the preferred first-line test for evaluating suspected hypothyroidism or hyperthyroidism.

Clinical roleTSH is used as the initial screening test for thyroid dysfunction; abnormal TSH prompts reflex measurement of free T4 (or additional testing per clinical context).

Testing noteTSH assay interpretation should consider clinical context (pregnancy, pituitary disease) and method-specific reference ranges; extremely low values may require confirmatory testing and evaluation for thyrotoxicosis.

fT4 / fT3 — Free thyroxine and free triiodothyronine definitions

DefinitionsFree thyroxine (fT4) and free triiodothyronine (fT3) represent the unbound, biologically active fractions of T4 and T3 in serum used to confirm and characterize thyroid dysfunction.

Policy Summary

PayerCapital Bluecross

PolicyThyroid Disease Testing

Policy CodePolicy AHS - G2045 - Thyroid Disease Testing

Change TypeNo material change

Effective Date

Next Review Date

Key ActionStart evaluation with TSH as the preferred first-line test and document clinical indications when ordering additional thyroid tests.

SourceLink

On This Page

Clinical context should justify additional tests beyond TSH.

Multiple ATA pregnancy recommendations

When to measure T3/fT3: Do not routinely measure total or free T3 to assess hypothyroidism or to monitor levothyroxine dose; measure T3/fT3 when thyrotoxicosis is suspected or when suppressed TSH requires evaluation of hyperthyroidism etiology.

ATA, Endocrine Society recommendations

Central hypothyroidism diagnosis and monitoring: In suspected central hypothyroidism, measure combined FT4 and TSH. Confirm diagnosis with FT4 below the reference range and inappropriately low/normal TSH on at least two determinations; monitor FT4 and TSH biannually in childhood and annually thereafter for hypothalamic‑pituitary disease.FT4 decrease >20% of prior values may be significant

ETA guidance

Testing around immune reconstitution therapy (IRT) and alemtuzumab: Measure TSH before IRT and perform periodic TSH every 3 months after alemtuzumab for up to 4 years; if TSH is abnormal, measure FT4 and FT3 as recommended with specific repeat intervals based on degree of abnormality.TSH monitoring every 3 months post‑alemtuzumab

ETA recommendations

Evaluate for CeH after initiation of recombinant human growth hormone (rhGH) or estrogen, and in patients treated with RXR ligands, checkpoint inhibitors (eg, ipilimumab), or mitotane.

ETA recommendation to evaluate CeH after these exposures

Monitoring frequency for children on levothyroxine: Age‑based intervals: children >=2 years measure FT4 and TSH every 6–12 weeks until TSH stabilized (2 similar measures 3 months apart), then every 4–6 months until after puberty, then annually; children <2 years measure every 4–8 weeks until stabilized (2 similar measures 2 months apart), then at specified intervals in first and second years.age‑based intervals

NICE recommendations

For monitoring on therapy, follow recommended intervals (e.g., every 4–6 weeks after dose change; annually when stable)

Documentation Required

Clinical Documentation Requirements

Document the clinical context when ordering tests: record signs/symptoms consistent with hypothyroidism or hyperthyroidism, pregnancy or postpartum status (include trimester), exposures to medications or agents that affect thyroid function (e.g., amiodarone, lithium, iodinated contrast), and relevant history such as prior Graves' disease or thyroid surgery.

Document presence of signs/symptoms consistent with thyroid dysfunction
Document pregnancy/postpartum status and trimester-specific information
Document medication exposures or recent radiologic contrast

Documentation Required

Support Documentation for Extended Pregnancy Testing

Support documentation is required when ordering extended pregnancy-related testing beyond first-line TSH/fT4. Provide rationale (e.g., prior Graves' disease treated with radioactive iodine or thyroidectomy, elevated prior TRAb, clinical suspicion of fetal/neonatal risk) and note trimester-specific reference ranges used for interpretation.

When ordering TRAb, state history of Graves' disease or prior ablation/surgery
Document trimester-specific reference ranges and rationale for repeat TRAb testing (eg, elevated early pregnancy result)
For hyperthyroid pregnant patients, document need for TT3/total T3 if T3 thyrotoxicosis suspected

Denial Risk

Denial Risk from Non‑Guideline Testing

Certain tests are not routinely covered and carry denial risk if ordered without an indicated reason. Testing for TRH stimulation, TBG, reverse T3, T3 uptake, and routine TT4 in contexts not outlined by policy may be denied. Measurement of TT3 or fT3 to assess hypothyroidism or to adjust levothyroxine dose does not meet coverage criteria and may be denied.

Tests that may be denied if not indicated: TRH stimulation (80438/80439), TBG (84442), reverse T3 (84482), T3 uptake (84479)
Do not order TT3 or fT3 to assess hypothyroidism or to guide LT4 dosing; this may be denied

Denial Risk

Overuse Risk from Non‑Guideline Testing

Overuse of free hormone testing in place of a TSH-first strategy increases costs and may lead to unnecessary downstream testing. Use guideline-recommended algorithms (TSH-first, then reflex/add fT4 or fT3 as clinically indicated) to avoid inappropriate utilization.

Avoid ordering fT4 and/or fT3 reflexively without abnormal TSH unless clinically indicated
Clinician audit: free hormone testing comprised a substantial portion of tests and drives avoidable cost

Billing Rule

Listed Procedure Codes for Thyroid Testing

Procedure codes relevant to thyroid testing are listed for billing reference. Providers should reference these CPT/HCPCS codes when ordering and billing; presence of a code here is informational and does not by itself guarantee coverage — coverage depends on meeting clinical criteria and applicable benefit rules.

Common CPT codes: 80438, 80439 (TRH panels); 83519, 83520 (immunoassays); 84432 (thyroglobulin); 84436 (total T4); 84439 (free T4); 84442 (TBG); 84443 (TSH); 84445 (TSI); 84479 (T3/T4 uptake); 84480 (TT3); 84481 (fT3); 84482 (reverse T3); 86376 (microsomal antibodies); 86800 (thyroglobulin antibody)
Procedure codes are provided for reference and may not be all‑inclusive

Note

Government Policy Precedence

If there is a conflict between this policy and any applicable government policy (e.g., Medicare LCDs/NCDs or state Medicaid rules), the government policy takes precedence and will be used to make coverage determinations.

Refer to CMS Medicare Coverage Database and applicable state Medicaid websites for up-to-date government policy
Government (LCD/NCD/Medicaid) policy supersedes payer policy when applicable

Note

Prior Authorization and Denial Criteria Note

No explicit prior authorization requirements or denial criteria are contained within this reference section beyond the coverage guidance and denial risks noted; coverage decisions depend on meeting the clinical indications and documentation requirements enumerated in the policy and applicable benefit terms.

This section does not specify prior authorization procedures
Absence of a denial criterion here does not guarantee coverage without meeting clinical criteria

Note

Not Specified in This Portion of the Document

Some elements are not specified in this portion of the document. Providers should consult the full policy, benefit contract, and applicable government guidance for any procedures, exceptions, or operational rules not described here.

When in doubt, document clinical rationale and reference guideline recommendations (ACOG, ATA, AACE, ETA, ASCP, Endocrine Society, NICE, SMFM)
Contact payer or utilization management for prior authorization/process questions

Clinical usefT4 is the preferred confirmatory test when TSH is abnormal (especially to diagnose hypothyroidism); fT3 (or total T3) is used selectively when thyrotoxicosis is suspected or to evaluate T3 thyrotoxicosis.

Guideline cautionSociety guidance recommends avoiding routine measurement of T3/fT3 for monitoring levothyroxine dosing in hypothyroid patients; reserve fT3 for specific indications.

Autoimmune thyroiditis — definition including antibody associations

DefinitionAutoimmune thyroiditis — chronic autoimmune inflammation of the thyroid (includes Hashimoto's, painless, and postpartum thyroiditis) commonly associated with elevated antithyroglobulin (Tg) and antithyroid peroxidase (TPO) antibodies.

Clinical courseForms such as Hashimoto's typically lead to persistent hypothyroidism; painless and postpartum thyroiditis often have an initial thyrotoxic phase followed by hypothyroidism, with ~80% resolving within 12–18 months.

Antibody testing roleMeasurement of Tg-Ab and TPOAb assists evaluation of suspected autoimmune thyroiditis and is considered in subclinical hypothyroidism and recurrent miscarriage workups per guideline recommendations.

Trimester-specific TSH reference ranges (ATA recommended)

First trimester0.1–2.5 mIU/L

Second trimester0.2–3.0 mIU/L

Third trimester0.3–3.0 mIU/L

Central hypothyroidism (CeH) — definition requiring repeated measures and clinical context

DefinitionCentral hypothyroidism (CeH) — thyroid dysfunction due to hypothalamic or pituitary disease characterized by low serum FT4 accompanied by an inappropriately low or normal TSH.

Confirmatory requirementDiagnosis requires combined FT4 and TSH determinations with FT4 below the lower limit and inappropriately low/normal TSH on at least two separate measurements, after excluding other causes.

Clinical contextConsider CeH in neonates/children with congenital hypothyroidism but low/normal neonatal TSH and in patients with hypothalamic–pituitary lesions, head trauma, cranial irradiation, hemochromatosis, or other pituitary disease manifestations.

TRAb / TSHRAb — definition and use in Graves' disease and pregnancy

DefinitionTRAb / TSHRAb (thyrotropin receptor autoantibodies) — antibodies directed against the TSH receptor used to evaluate Graves' disease and help guide management, especially in pregnancy.

Clinical useMeasure TRAb in pregnant patients with a history of Graves' disease (e.g., treated with radioactive iodine or thyroidectomy) around 20–24 weeks or earlier as indicated to assess fetal risk and guide monitoring.

Diagnostic roleTRAb is a sensitive and specific tool for differentiating Graves' hyperthyroidism and is useful prior to stopping antithyroid drug therapy or when predicting extrathyroidal manifestations.

Central hypothyroidism (CeH) — duplicate definition entry (confirmatory emphasis)

Core definitionCentral hypothyroidism (CeH) — characterized by serum FT4 below the normal range with inappropriately low or normal TSH; consider when screening shows low FT4 with low/normal TSH.

Diagnostic confirmationConfirm CeH by combined FT4 and TSH testing on at least two separate occasions and exclude non-thyroidal illness and listed conditions before making the diagnosis.

Monitoring recommendationFor patients with hypothalamic–pituitary disease, monitor FT4 and TSH at least biannually in childhood and yearly thereafter; consider CeH when FT4 falls into the lower quartile or decreases >20% from prior values despite low/normal TSH.

Clinical guidelines — referenced society guidelines used across the policy

Primary guideline sourcesAmerican Thyroid Association (ATA), American Association of Clinical Endocrinologists (AACE), Endocrine Society (ES), European Thyroid Association (ETA).

Pregnancy guidanceATA pregnancy guidelines and ACOG practice bulletin — recommend trimester-specific ranges and pregnancy-specific management approaches.

Specialty recommendationsASCP, NICE, SMFM and AJGP provide testing cascade, monitoring intervals, and screening recommendations referenced in this policy.